Beijing Beilu Pharmaceutical Co (300016) Fair Value & Analysis

Healthcare · CN · Market cap 4.4B CNY

Analysis

Beijing Beilu Pharmaceutical Co (300016) currently trades at ¥7.57, while our model-based Fair Value estimate is ¥3.12 — implying the stock looks roughly 58.8% overvalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

About the company

Beijing Beilu Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of pharmaceutical products in China. The company provides contrast agents, such as gadopentetate meglumine injection, gadobutrol injection, and gadobenate meglumine injection for MRI contrast; and iohexol injection, iopamidol injection, and iodixanol injection for CT contrast, as well as glimepiride and repaglinide tablets and jiuwei zhenxin granules. It also offers gadolinium-based agents, including gadopentetate dimeglumine and gadobutrol, as well as iodine-based agents comprising iohexol, ioversol, iodixanol, iopromide, and iopamidol, as well as oral anti-diabetic drugs. The company was founded in 1992 and is based in Beijing, China.

Open the full interactive analysis →

Similar stocks

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.